DCE-MRI Demonstrates Antivascular Properties of Sorafenib in Metastatic Hormone-Resistant Prostate Cancer

Mark Alan Rosen¹, Ganesh Adluru¹, Ravi Amaravadi², Yiqun Xue¹, Yu Jiangsheng¹, Hee-Kwon Song¹, Naomi Haas², Peter O'Dwyer²

DCE-MRI using large-volume radial imaging was used to gauge response of metastatic prostate cancer to combination therapy including the anti-angiogenic agent, sorafenib. We observed strong anti-vascular response of tumors to a seven-day course of sorafenib. This effect was reversed on follow-up DCE-MRI at day 21, after a mandated three-day sorafenib free-interval, suggesting that the sorafenib effects on tumor were rapidly reversible. We also noted that alterations in tumor vascularity, as reflected in changes in tumor AUC60, were negatively correlated with early changes in serum PSA levels, in concert with clinical results revealing sorafenibs potential to increase PSA levels.